Histogenics Corp (NASDAQ:HSGX) shares were up 0.7% during mid-day trading on Tuesday . The stock traded as high as $2.95 and last traded at $2.83. Approximately 3,209 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 242,259 shares. The stock had previously closed at $2.85.
Several research analysts have issued reports on HSGX shares. HC Wainwright reiterated a “buy” rating and issued a $3.50 price objective on shares of Histogenics in a research report on Monday, August 13th. Brookline Cap M reiterated a “buy” rating on shares of Histogenics in a research report on Wednesday, August 1st. Zacks Investment Research cut Histogenics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. ValuEngine cut Histogenics from a “hold” rating to a “sell” rating in a research report on Thursday, May 17th. Finally, BTIG Research cut Histogenics from a “buy” rating to a “neutral” rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $2.92.
The firm has a market cap of $85.37 million, a price-to-earnings ratio of -0.78 and a beta of 1.69.
Histogenics (NASDAQ:HSGX) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.10. analysts expect that Histogenics Corp will post -0.71 EPS for the current year.
Institutional investors have recently bought and sold shares of the business. Archon Capital Management LLC acquired a new stake in Histogenics in the first quarter valued at $639,000. JPMorgan Chase & Co. acquired a new stake in Histogenics in the first quarter valued at $320,000. Sofinnova Ventures Inc acquired a new stake in Histogenics in the first quarter valued at $5,712,000. Deutsche Bank AG grew its holdings in Histogenics by 71.1% in the fourth quarter. Deutsche Bank AG now owns 71,706 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 29,806 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT acquired a new stake in Histogenics in the first quarter valued at $199,000. 45.89% of the stock is currently owned by institutional investors.
Histogenics Company Profile (NASDAQ:HSGX)
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Recommended Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.